anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
ruthenium complexes. The present invention relates to a new variety of ruthenium complexes, comprising a derivative of Ru with indenyl and dmoPTA or HdmoPTA. These complexes combine solubility in water, high activity and specificity against different biomolecules, as well as stability in air and easy administration. Additionally, the complexes present specific activity against biomolecules, both in intensity and activity, constituting the basis of a series of drugs that can act specifically against certain targets and the diseases in which they participate. The invention also refers to different procedures for obtaining said ruthenium complexes, as well as their use as medicines or in the treatment of cancer.   (Machine-translation by Google Translate, not legally binding)
This is a single arm pilot study. Investigators planned to enroll approximately 10 patients to receive concurrent intrathecal DepoCyt and oral Sorafenib. DepoCyt: through a reservoir every 2 weeks for 5 doses, then every 4 weeks for an additional 5 doses (a total of 10 DepoCyt treatments). Oral Sorafenib: at 400 mg twice a day throughout the treatment course until disease progression or death.
Risk Summary

Based on the mechanism of action, EPKINLY may cause fetal harm when administered to a pregnant woman [see Clinical Pharmacology (12.1)]. There are no available data on the use of EPKINLY in pregnant women to evaluate for a drug-associated risk. No animal reproductive or developmental toxicity studies have been conducted with epcoritamab-bysp.

Epcoritamab-bysp causes T-cell activation and cytokine release; immune activation may compromise pregnancy maintenance. In addition, based on expression of CD20 on B-cells and the finding of B-cell depletion in non-pregnant animals, epcoritamab-bysp can cause B-cell lymphocytopenia in infants exposed to epcoritamab-bysp in-utero. Human immunoglobulin G (IgG) is known to cross the placenta; therefore, EPKINLY has the potential to be transmitted from the mother to the developing fetus. Advise women of the potential risk to the fetus.

In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.
PURPOSE:To obtain the title juice with a combination of efficacies due to tomato and aloe along with light and soft drinking feel, by heating each ground tomato and aloe at specified temperatures for specified time followed by mixing and bottling. CONSTITUTION:Firstly, washed tomatoes and aloes are each ground, and heated, respectively, pref. at ca. 85 deg.C for 40-70min. Thence, the resultant respective juices are mutually mixed in the weight ratio tomato/aloe = 100/5-6 followed by filling in bottles of specified volume. The resultant product is heated for 35-40min, thus obtaining the objective tomato juice.
The study will be conducted among men referred to prostate biopsy due to clinical suspicion of malignancy. 100 consecutive patients will undergo prostate biopsies. Biopsies will be taken from both lobes of the prostate (standard protocol) and additional biopsies will be taken according to MRI findings (Fusion biopsies) if relevant. One additional biopsy will be taken from each lobe of the prostate and immediately freezed in -80 Celsius degrees. Routine biopsies will be fixed in formaldehyde and embedded in paraffin and will undergo routine pathological analysis and staining.

Following pathological analysis, paraffin slides will be undergo immunohistochemically staining for PKA, comparing cancerous tissue to normal surrounding tissue. the fresh frozen tissue will undergo western blot analysis for quantitative expression of PKA and its sub units.
Anaphylactic reactions and other allergic reactions have been reported with isotretinoin use. Cutaneous allergic reactions and serious cases of allergic vasculitis, often with purpura (bruises and red patches) of the extremities and extracutaneous involvement (including renal) have been reported. Severe allergic reaction necessitates discontinuation of therapy and appropriate medical management.

Allergic Reactions Due to the Inactive Ingredient (FD&C Yellow No. 5) in the 25 mg ABSORICA Capsule

The 25 mg ABSORICA capsule contains FD&C Yellow No. 5 (tartrazine) which may cause allergic-type reactions (including bronchial asthma) in certain susceptible persons. Although the overall incidence of tartrazine sensitivity in the general population is low, it is frequently seen in patients who also have aspirin hypersensitivity. The 10 mg, 20 mg, 30 mg, 35 mg, and 40 mg ABSORICA capsules do not contain FD&C Yellow No. 5 and all of the ABSORICA LD capsules do not contain FD&C Yellow No. 5. Thus, in patients with allergic reactions to tartrazine, avoid using the 25 mg ABSORICA capsules.
Adolescent idiopathic scoliosis (AIS) is the most common spinal deformity in adolescents and literature suggests that the link between back pain and AIS is underreported. Core stabilization exercises and scoliosis specific exercises have been shown to increase SRS scores related to pain (higher SRS scores indicate lower levels of pain). Additionally, higher SRS scores at pre-op were associated with a lower risk of residual postoperative pain following a fusion surgery. This suggests that preoperative exercise programs should lead to an increase in SRS pain scores post-operatively however, this direct relationship has not been researched. Rehabilitation exercises prior to surgery has been shown to improve functional outcomes in knee and hip arthroplasties however, the rehabilitation preoperatively has not been studies in the context of spine surgeries. The purpose of this study is to evaluate whether the prehabilitation exercise program can improve post-op outcomes including length of stay, decreased pain, decreased length of stay, and improved functional outcomes.
A crosslinked cation exchange polymer for use in removing potassium from the gastrointestinal (GI) tract of an animal subject in need thereof wherein less than 25% of subjects taking the polymer or composition once per day experience mild or moderate GI adverse events. The preferred polymer to be crosslinked is poly(Î±-fluoroacrylic acid) in salt form. The preferred crosslinking agent is divinylbenzene (DVB). The crosslinked cation exchange polymers have beneficial physical properties, including combinations of particle size, particle shape, particle size distribution, viscosity, yield stress, compressibility, surface morphology, and/or swelling ratio. The polymers may be formulated into pharmaceutical compositions, such as with a linear polyol, especially sorbitol and/or xylitol. These polymers and/or compositions bind to potassium in the GI tract, and are thus are particularly useful for the treatment of hyperkalemia.
The present invention provides compositions and methods for the treatment of cell proliferative disorders using at least one DAC inhibitor and at least one tyrosine kinase inhibitor. In particular, the invention provides a combination therapy for treating a proliferative disorder (e.g., cancer) including romidepsin and a tyrosine kinase inhibitor. When administered together, romidepsin and a tyrosine kinase inhibitor (e.g., erlotinib) interact to induce apoptosis. The effect is particularly pronounced in wild type non-small cell lung cancers, particularly wild type EGFR and wild type KRAS non-small cell lung cancer cells. The invention provides methods of killing malignant cells in vitro and in vivo. Pharmaceutical compositions, preparations, and kits including romidepsin and a tyrosine kinase inhibitor are also provided.
Infants who met the inclusion and exclusion criteria, respectively, were accepted to participate in the study. The randomization of the sample was performed by a statistician, who had no prior contact with either the infants or the parents. The online Randomizer (www.randomizer.org) program was used to randomly generate 200 sets of numbers, each containing two numbers ranging from 1 to 2 in random order. After signing the consent, a code was randomly chosen for each patient, thus ensuring that the 200 patients were equally distributed into two groups according to the group number of each code: group 1 (Myofunctional Therapy group) and group 2 (group sessions lactation).

Infants who met the inclusion criteria were referred to the rehabilitation and physiotherapy service. A physical therapist outside the study was in charge of evaluating the measurements of all infants during the first week of life through all the scales detailed below (pre-test). After randomly assigning the infants, another physiotherapist was responsible for applying the intervention once a week for 30 minutes for a period of 30 days. Once the intervention was finished, all the infants (both intervention groups) were reassessed by the physiotherapist outside the study using the same baseline scales (post-test).
Patients receive 15\*10\^9 U/m2/d recombinant interferon a-2B intravenously on days 1-5. Treatment repeats weekly for 4 weeks in the absence of disease progression or unacceptable toxicity.Then patients receive 15\*10\^9 U/m2/d recombinant interferon a-2B intravenously three times weekly for 48 weeks.
TGF-β1 plays a pivotal role in the metastatic cascade of malignant neoplasms. N6-methyladenosine (m6A) stands as one of the most abundant modifications on the mRNA transcriptome. However, in the metastasis of gallbladder carcinoma (GBC), the effect of TGF-β1 with mRNA m6A modification, especially the effect of mRNA translation efficiency associated with m6A modification, remains poorly elucidated. Here we demonstrated a negative correlation between FOXA1 and TGF-β1 expression in GBC. Overexpression of FOXA1 inhibited TGF-β1-induced migration and epithelial-mesenchymal transition (EMT) in GBC cells. Mechanistically, we confirmed that TGF-β1 suppressed the translation efficiency of FOXA1 mRNA through polysome profiling analysis. Importantly, both in vivo and in vitro experiments showed that TGF-β1 promoted m6A modification on the coding sequence (CDS) region of FOXA1 mRNA, which was responsible for the inhibition of FOXA1 mRNA translation by TGF-β1. We demonstrated through MeRIP and RIP assays, dual-luciferase reporter assays and site-directed mutagenesis that ALKBH5 promoted FOXA1 protein expression by inhibiting m6A modification on the CDS region of FOXA1 mRNA. Moreover, TGF-β1 inhibited the binding capacity of ALKBH5 to the FOXA1 CDS region. Lastly, our study confirmed that overexpression of FOXA1 suppressed lung metastasis and EMT in a nude mice lung metastasis model. In summary, our research findings underscore the role of TGF-β1 in regulating TGF-β1/FOXA1-induced GBC EMT and metastasis by inhibiting FOXA1 translation efficiency through m6A modification.
SARS-CoV-2 mediated infection instigated a scary pandemic state since 2019. They created havoc comprising death, imbalanced social structures, and a wrecked global economy. During infection, the inflammation and associated cytokine storm generate a critical pathological situation in the human body, especially in the lungs. By the passage of time of infection, inflammatory disorders, and multiple organ damage happen which might lead to death, if not treated properly. Until now, many pathological parameters have been used to understand the progress of the severity of COVID-19 but with limited success. Bioactive lipid mediators have the potential of initiating and resolving inflammation in any disease. The connection between lipid storm and inflammatory states of SARS-CoV-2 infection has surfaced and got importance to understand and mitigate the pathological states of COVID-19. As the role of eicosanoids in COVID-19 infection is not well defined, available information regarding this issue has been accumulated to address the possible network of eicosanoids related to the initiation of inflammation, promotion of cytokine storm, and resolution of inflammation, and highlight possible strategies for treatment and drug discovery related to SARS-CoV-2 infection in this study. Understanding the involvement of eicosanoids in exploration of cellular events provoked by SARS-CoV-2 infection has been summarized as an important factor to deescalate any upcoming catastrophe imposed by the lethal variants of this micro-monster. Additionally, this study also recognized the eicosanoid based drug discovery, treatment, and strategies for managing the severity of SARS-COV-2 infection.
Patients receive oral temozolomide once daily on days 1-42. Patients also undergo concurrent radiotherapy once daily on days 1-5, 8-12, 15-19, 22-26, 29-33 and 36-40. Patients who did not undergo prior gross total resection also undergo boost radiotherapy once daily on days 43-47. Four weeks after completion of chemoradiotherapy, patients receive oral temozolomide once daily on days 1-5 and oral lomustine on day 1. Treatment repeats every 42 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
In this arm, participants have a phone-based Baseline visit followed by the 1st phone-based Coaching visit. No prompting devices/desks are offered; coaching focuses on topics related to healthy living, but with no focus on sitting less/standing more. They have 10 phone calls with a health coach. Participants receive a workbook. All content is from KaiserPermanente WA and is available to all members. Participants select topics \& review them with their health coach. At 3 months, participants have a measurement visit. The program ends at 6 months where participants will wear an activPAL and have a measurement visit. After that, there is no contact with the study team until 12 months when they will again wear an activPAL \& have a final measurement visit. UPDATE: As of 3/31/2022, our final year (year 5) of the study, participants randomized to the control arm will no longer be followed to the 12-month timepoint and will end all activities after the 6-month timepoint.
PURPOSE: To obtain an antienzyme against esterase and lipase, containing ebelactone B and/or ebelactone A as an active ingredient and to provide an inhibitor for hyperlipemia having high inhibitory activity against hyperlipemia. CONSTITUTION: This antienzyme contains ebelactone B or ebelactone A or both as active ingredients. Ebelactone B and ebelactone A have inhibitory activity against lipase and esterase enzyme, suppresses absorption of fats and represses an amount of triglyceride in serum. The antienzyme is useful for studying the role of lipase or esterase in hyperlipemia. An inhibitor for hyperlipemia is obtained by properly mixing ebelactone B and/or ebelactone A with a conventional preparation auxiliary and pharmaceutically manufacturing the mixture by a conventional method into a preparation for oral administration. A dose is 0.1-2.5g per adult and is properly administered one hour before each meal. Ebelactone B shows stronger inhibitory activity against esterase and lipase than ebelactone A.
This multicenter, randomized, double-blind, placebo-controlled trial was designed to determine whether daily antimicrobial prophylaxis is superior to placebo in preventing recurrence of urinary tract infection (UTI) in children with vesicoureteral reflux (VUR). Eligibility criteria are described elsewhere. Patients were randomly assigned to treatment for 2 years with daily antimicrobial prophylaxis (trimethoprim-sulfamethoxazole) or placebo. The study was designed to recruit 600 children (approximately 300 in each treatment group). The protocol encouraged prompt evaluation of children with UTI symptoms and early therapy of culture-proven UTIs. It was expected that approximately 10% of children will have to discontinue study medication due to allergic reactions. Assuming a 20% placebo event rate and 10% non-compliance rate, the study has 83% power to detect an absolute 10% event rate in the antimicrobial prophylaxis group. If the placebo event rate is instead 25%, power is 97% to detect an absolute 10% event rate in the treated group, even if non-compliance is as high as 15%. The primary analysis is intention-to-treat with missing outcome data analyzed as UTI.

In addition to collecting follow-up data on urinary tract infections, renal scarring and antimicrobial resistance, quality of life, compliance, safety parameters, utilization of health resources, and change in VUR were assessed periodically throughout the study.
A composition of bupivacaine encapsulated multivesicular liposomes (MVLs) comprising bupivacaine residing within a plurality of internal aqueous chambers of the MVLs separated by lipid membranes comprising 1,2-dierucoylphosphatidylcholine (DEPC), 1,2-dipalmitoyl-sn-glerco-3-phospho-rac-(1-glyerol) (DPPG) and at least one neutral lipid; and an aqueous medium in which the bupivacaine encapsulated MVLs are suspended; wherein the composition has an erucic acid concentration of 24µg/mL or less after being stored at 25°C for one month. The composition may have an initial pH of 7.4. The lipid membranes may further comprise cholesterol and tricaprylin. The internal aqueous chambers may comprise lysine and/or dextrose, particularly at a concentration of 0.03µg/mL and 1.25-1.32µg/mL respectively. A process for preparing bupivacaine encapsulated multivesicular liposomes defined above is also provided. The bupivacaine MVLs may have a percent packed particle volume of 35-40%. The compositions are disclosed to be useful in treating or ameliorating pain, particularly via local infiltration to a surgical site; via interscalene brachial plexus nerve block or via femoral nerve block to provide regional analgesia.
Visual impairment severely impacts the life of the patients. In this study, we systematically reviewed studies on the potential relationship between visual impairment and suicidal behaviour, and conducted meta-analyses on the risk estimates. We searched 11 literature databases on 20 October 2022 and identified a total of 10 eligible studies with 5.8 million participants. Suicide behaviour was investigated according to three domains: suicide ideation, suicide attempt and suicide death. In the 10 eligible studies, seven reported data on suicide ideation, five reported data on suicide attempt, and three reported data on suicide death. All summary estimates extracted for use in the meta-analyses were adjusted estimates of association since we acknowledged that depression as well as other confounding factors may play an important role. We found that visual impairment was a significant risk factor of suicide ideation (OR 1.83; 95% CI: 1.40-2.40; p = 0.000012), suicide attempt (OR 2.62; 95% CI: 1.29-5.31; p = 0.0077) and suicide death (OR 7.00; 95% CI: 2.30-21.4; p = 0.000063). These high increases in risk of suicide from visual impairment underscore the importance of eye health on the overall mental health, and the potential devastating consequences of insufficient access to eye care, lack of treatment possibilities for any reason or low political priority of eye care.
The invention discloses a Chinese medicinal composition for treating depression. The medicine adopts lilies, semen ziziphi apinosae, curcuma longa, hypericum perforatum L., perilla, ginseng, and radix bupleuri as raw materials, which are then separate and extracted by 0-75% ethanol so as to be prepared into certain preparation form. The above six drugs used together can soothe liver and relieve depression, reconcile and activate qi, tranquilize the mind and calm the nerves, and can be used for mild and moderate depression and patients belonging to stagnation of qi due to depression of liver, as well as heart-spleen deficiency. Pharmacodynamic research indicates that: the medicinal composition has substantial antagonistic effects on reserpine induced depression models, mouse akinesia and hypothermia, and can increase the spontaneous movements of tail suspension and forced swimming induced despair animal models, as well as the immobility time of tail suspension and swimming. Clinical research results show that a HAMD (Hamilton depression scale) used for evaluating depression severity and Chinese medicinal syndromes before and after treatment are taken as main curative effect indexes, which show that the Chinese medicinal composition in the invention has substantial curative effects. The composition provided in the invention can be prepared into medically acceptable oral preparations, such as tablets, capsules (soft capsules and hard capsules), granules, and other preparation forms. Clinical effects and pharmacodynamic research prove that the Chinese medicinal composition of the invention has the functions of liver soothing and depression relieving, mind tranquilizing as well as nerve calming, and is an effective medicine special for depression treatment.
The invention discloses a Chinese medicament for treating mammary gland hyperplasia. The Chinese medicament is characterized by consisting of the following components by weight: 30 to 65 grams of dandelion, 20 to 35 grams of Chinese angelica, 20 to 35 grams of costus root, 20 to 35 grams of angelica dahurica, 20 to 35 grams of mint, 20 to 35 grams of gardenia, 10 to 25 grams of Chinese violet, 10 to 25 grams of snake gourd fruit, 10 to 25 grams of astragalus root, 10 to 25 grams of curcuma, 10 to 25 grams of tangerine leaf, 10 to 20 grams of oyster, 10 to 20 grams of self-heal, 6 to 15 grams of red peony root, and 8 to 12 grams of bupleurum. The Chinese medicinal components are aired or dried and crushed into fine powder. The medicinal powder is applied on navel. The Chinese medicament for treating the mammary gland hyperplasia is preferably selected through years of concentrative study and summarization. The Chinese medicament is reasonable in formula, easy to prepare and convenient to use; and by years of clinical application verification, the Chinese medicament is remarkable in curative effect and mild and does not have toxic or side effect, the effective rate is 80 percent, and the cure rate is 70 percent.
OBJECTIVE: Our objective was to determine the frequency of rotavirus, adenovirus, and rota-adenovirus co-infections and investigate the fecal leukocyte rate associated with these infections in patients with gastroenteritis.
METHODS: This is a retrospective study. We identified patients who were admitted to the pediatric emergency department with acute gastroenteritis and had their stool samples tested for rotavirus and/or adenovirus antigens. Among them, we determined the individuals who underwent stool microscopy tests on the same day and recorded their results.
RESULTS: A total of 1,577 patients who underwent testing for rotavirus and/or adenovirus antigens in their stool samples were identified. Among these patients, 583 individuals had concurrent fecal microscopy results. The prevalence of solely rotavirus antigen positivity was 16.4%, solely adenovirus antigen positivity was 2.9%, and rota-adenovirus co-infections were detected in 1.8% of the children. The fecal leukocyte rates in children infected with rotavirus, adenovirus, and rota-adenovirus co-infections were 4.8, 13.3, and 88.9%, respectively.
CONCLUSION: The presence of fecal leukocytes was detected at a high rate in cases of viral gastroenteritis, especially in rota-adenovirus co-infections. Therefore, clinicians should not consider only bacterial pathogens in the presence of fecal leukocytes.